Clear Gene Revenue and Competitors

We detect residual solid tumor. Residual tumor is cancer that remains after a treatment. Patients with liquid tumors benefit from a series of technical revolutions to detect residual disease. But patients with solid tumors have been left behind. Until now. No one wants to receive unnecessary cancer treatments. We use advances in genomics and machine learning to detect residual solid tumors. We ultimately hope to improve tests for solid tumors to the point that individual patients can safely reduce treatments once their tumor has been eradicated.